Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 2 (2005), Issue 1 (January)

1. Risk and protective factors for Parkinson's disease: a study in Swedish twins.
   Ann Neurol, 57(1): 27-33. [Abstract] [Full-text]
2. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model.
   J Clin Invest, 115(1): 102-9. [Abstract] [Full-text]
3. The promise of stem cells in Parkinson disease.
   J Clin Invest, 115(1): 23-5. [Abstract] [Full-text]
4. Ubiquitin-proteasome system and Parkinson's diseases.
   Exp Neurol, 191: S17-27. [Abstract] [Full-text]
5. The effect of Parkinson's disease on the control of multi-segmental coordination.
   Brain Cogn, 57(1): 16-20. [Abstract] [Full-text]
6. Peroperative transcranial sonography for electrode placement into the targeted subthalamic nucleus of patients with Parkinson disease: technical note.
   Surg Neurol, 63(1): 66-9; discussion 69. [Abstract] [Full-text]
7. Impaired procedural learning in obsessive-compulsive disorder and Parkinson's disease, but not in major depressive disorder.
   Behav Brain Res, 157(2): 253-63. [Abstract] [Full-text]
8. Quality index for the quantification of the information recorded along standard microelectrode tracks to the subthalamic nucleus in parkinsonian patients.
   Neurophysiol Clin, 34(5): 209-15. [Abstract] [Full-text]
9. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation.
   Neurology, 64(1): 134-6. [Abstract] [Full-text]
10. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
    Neurology, 64(1): 87-93. [Abstract] [Full-text]
11. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study.
    Neurology, 64(1): 81-6. [Abstract] [Full-text]
12. Stimulation of the subthalamic nucleus in a patient with Parkinson disease and essential tremor.
    Arch Neurol, 62(1): 141-3. [Abstract] [Full-text]
13. Failure to find alpha-synuclein gene dosage changes in 190 patients with familial Parkinson disease.
    Arch Neurol, 62(1): 96-8. [Abstract] [Full-text]
14. Pesticides and risk of Parkinson disease: a population-based case-control study.
    Arch Neurol, 62(1): 91-5. [Abstract] [Full-text]
15. A rare truncating mutation in ADH1C (G78Stop) shows significant association with Parkinson disease in a large international sample.
    Arch Neurol, 62(1): 74-8. [Abstract] [Full-text]
16. Sleep microstructure and neurodegeneration as measured by [123I]beta-CIT SPECT in treated patients with Parkinson's disease.
    J Neurol, 251(12): 1465-71. [Abstract] [Full-text]
17. Patterns of psychological problems in Parkinson's disease.
    Acta Neurol Scand, 111(2): 95-101. [Abstract] [Full-text]
18. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
    Acta Neurol Scand, 111(2): 89-94. [Abstract] [Full-text]
19. Analysis of gene expression changes in a cellular model of Parkinson disease.
    Neurobiol Dis, 18(1): 54-74. [Abstract] [Full-text]
20. Unsupervised Spike Sorting of extracellular electrophysiological recording in subthalamic nucleus of Parkinsonian patients.
    Biosystems, 79(1): 159-71. [Abstract] [Full-text]
21. Effects of bilateral subthalamic stimulation on gait kinematics and kinetics in Parkinson's disease.
    Exp Brain Res, 160(4): 517-27. [Abstract] [Full-text]
22. Multiple pathologies in a patient with a progressive neurodegenerative syndrome.
    J Neurol Neurosurg Psychiatry, 76(2): 252-5. [Abstract] [Full-text]
23. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease.
    J Neurol Neurosurg Psychiatry, 76(2): 249-51. [Abstract] [Full-text]
24. Subthalamic nucleus stimulation in tremor dominant parkinsonian patients with previous thalamic surgery.
    J Neurol Neurosurg Psychiatry, 76(2): 246-8. [Abstract] [Full-text]
25. Quantitative assessment of driving performance in Parkinson's disease.
    J Neurol Neurosurg Psychiatry, 76(2): 176-80. [Abstract] [Full-text]
26. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Bioorg Med Chem, 13(3): 773-83. [Abstract] [Full-text]
27. Task-based profile of vocal intensity decline in Parkinson's disease.
    Folia Phoniatr Logop, 57(1): 28-37. [Abstract] [Full-text]
28. Differential progression of proprioceptive and visual information processing deficits in Parkinson's disease.
    Eur J Neurosci, 21(1): 239-48. [Abstract] [Full-text]
29. Study of verbal working memory in patients with Parkinson's disease.
    Neuropsychology, 19(1): 106-14. [Abstract] [Full-text]
30. Maintenance of response readiness in patients with Parkinson's disease: evidence from a simple reaction time task.
    Neuropsychology, 19(1): 54-65. [Abstract] [Full-text]
31. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    J Neural Transm, 112(2): 221-30. [Abstract] [Full-text]
32. Pergolide effect on cognitive functions in early-mild Parkinson's disease.
    J Neural Transm, 112(2): 231-7. [Abstract] [Full-text]
33. Ecstasy: pharmacology and neurotoxicity.
    Curr Opin Pharmacol, 5(1): 79-86. [Abstract] [Full-text]
34. Motor cortex dysfunction revealed by cortical excitability studies in Parkinson's disease: influence of antiparkinsonian treatment and cortical stimulation.
    Clin Neurophysiol, 116(2): 244-53. [Abstract] [Full-text]
35. Sudden failure of dual channel pulse generators.
    Mov Disord, 20(1): 64-6; discussion 66. [Abstract] [Full-text]
36. Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity.
    Mov Disord, 20(1): 100-3. [Abstract] [Full-text]
37. Genetic testing in Parkinson's disease.
    Mov Disord, 20(1): 1-10. [Abstract] [Full-text]
38. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease.
    Mov Disord, 20(1): 77-81. [Abstract] [Full-text]
39. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.
    Mov Disord, 20(1): 104-5. [Abstract] [Full-text]
40. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
    Mov Disord, 20(1): 69-72. [Abstract] [Full-text]
41. Three-dimensional gait biomechanics in Parkinson's disease: evidence for a centrally mediated amplitude regulation disorder.
    Mov Disord, 20(1): 40-50. [Abstract] [Full-text]
42. Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders.
    Neurology, 64(2): 230-5. [Abstract] [Full-text]
43. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease.
    Neurology, 64(2): 224-9. [Abstract] [Full-text]
44. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Neurology, 64(2): 216-23. [Abstract] [Full-text]
45. The role of radiotracer imaging in Parkinson disease.
    Neurology, 64(2): 208-15. [Abstract] [Full-text]
46. Cell transplantation in Parkinson's disease: how can we make it work?
    Trends Neurosci, 28(2): 86-92. [Abstract] [Full-text]
47. Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease.
    Neurosci Lett, 375(2): 112-6. [Abstract] [Full-text]
48. Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease.
    Am J Med Genet B Neuropsychiatr Genet, 133(1): 120-3. [Abstract] [Full-text]
49. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease.
    Am J Med Genet B Neuropsychiatr Genet, 133(1): 88-92. [Abstract] [Full-text]
50. Subthalamic nucleus stimulation for advanced Parkinson's disease: how to find a far medial STN.
    Minim Invasive Neurosurg, 47(6): 373-7. [Abstract] [Full-text]
51. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.
    J Neurosci, 25(4): 769-77. [Abstract] [Full-text]
52. PARK11 is not linked with Parkinson's disease in European families.
    Eur J Hum Genet, 13(2): 193-7. [Abstract] [Full-text]
53. Visuomotor dependency on an initial fixation target involved in the disorder of visually-guided manual movement in Parkinson's disease.
    Neurosci Res, 51(2): 167-73. [Abstract] [Full-text]
54. A common LRRK2 mutation in idiopathic Parkinson's disease.
    Lancet, 365(9457): 415-6. [Abstract] [Full-text]
55. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.
    Lancet, 365(9457): 412-5. [Abstract] [Full-text]
56. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.
    Lancet, 365(9457): 410-2. [Abstract] [Full-text]
57. Methionine oxidation, alpha-synuclein and Parkinson's disease.
    Biochim Biophys Acta, 1703(2): 157-69. [Abstract] [Full-text]
58. Postural stability of Parkinson's disease patients is improved by decreasing rigidity.
    Eur J Neurol, 12(2): 156-9. [Abstract] [Full-text]
59. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.
    Ann Neurol, 57(2): 298-302. [Abstract] [Full-text]
60. A responsive outcome for Parkinson's disease neuroprotection futility studies.
    Ann Neurol, 57(2): 197-203. [Abstract] [Full-text]
61. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo.
    Ann Neurol, 57(2): 176-9. [Abstract] [Full-text]
62. Microglial activation and dopamine terminal loss in early Parkinson's disease.
    Ann Neurol, 57(2): 168-75. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.